Arvind N. Dasari, MD, MS

Peer-Reviewed Articles

1. Dasari A, Lonardi S, Garcia-Carbonero R, Elez E, Yoshino T, Sobrero A, Yao J, García-Alfonso P, Kocsis J, Cubillo Gracian A, Sartore-Bianchi A, Satoh T, Randrian V, Tomasek J, Chong G, Paulson AS, Masuishi T, Jones J, Csoszi T, Cremolini C, Ghiringhelli F, Shergill A, Hochster HS, Krauss J, Bassam A, Ducreux M, Elme A, Faugeras L, Kasper S, Van Cutsem E, Arnold D, Nanda S, Yang Z, Schelman WR, Kania M, Tabernero J, Eng C, FRESCO-2 Study Investigators. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet 402(10395):41-53, 2023. e-Pub 2023. PMID: 37331369.
2. Peacock O, Manisundaram N, Dibrito SR, Kim Y, Hu CY, Bednarski BK, Konishi T, Stanietzky N, Vikram R, Kaur H, Taggart MW, Dasari A, Holliday EB, You YN, Chang GJ. Magnetic Resonance Imaging Directed Surgical Decision Making for Lateral Pelvic Lymph Node Dissection in Rectal Cancer after Total Neoadjuvant Therapy (TNT). Ann Surg 10(4):654-664, 2022. e-Pub 2022. PMID: 35837891.
3. Johnson B, Haymaker CL, Parra ER, Soto LMS, Wang X, Thomas JV, Dasari A, Morris VK, Raghav K, Vilar E, Kee BK, Eng C, Parseghian CM, Wolff RA, Lee Y, Lorenzini D, Laberiano-Fernandez C, Verma A, Lang W, Wistuba II, Futreal A, Kopetz S, Overman MJ. Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). J Immunother Cancer 8(8), 2022. PMID: 36007963.
4. Newhook TE, Overman MJ, Chun YS, Dasari A, Tzeng CD, Cao HST, Raymond V, Parseghian C, Johnson B, Nishioka Y, Kawaguchi Y, Uppal A, Vreeland TJ, Jaimovich A, Arvide EM, Cristo JV, Wei SH, Raghav KP, Morris VK, Lee JE, Kopetz S, Vauthey JN. Prospective Study of Perioperative Circulating Tumor DNA Dynamics in Patients Undergoing Hepatectomy for Colorectal Liver Metastases. Ann Surg 10. e-Pub 2022. PMID: 35797554.
5. Wong W, Perez Holguin RA, Olecki EJ, Stahl KA, Dixon M, Peng J, Dasari A, Shen C. Predictors and Outcomes of Minimally Invasive Surgery for Small Bowel Neuroendocrine Tumors : Minimally Invasive Surgery for SBNETs. J Gastrointest Surg 103(2):125-38, 2022. e-Pub 2022. PMID: 35132564.
6. Arvind Dasari, Yan Lin, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Ibrahim Halil Sahin, Dustin A. Deming, Philip Agop Philip, Theodore S. Hong, Yesenia Rojas-Khalil, Norman Wolmark, Greg Yothers, Thomas J. George, Christopher Hanyoung Lieu. Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US): NRG-GI008. Journal of Clinical Oncology(40):TPS3643-TPS3643, 2022.
7. Halperin DM, Liu S, Dasari A, Fogelman D, Bhosale P, Mahvash A, Estrella JS, Rubin L, Morani AC, Knafl M, Overeem TA, Fu SC, Solis LM, Parra Cuentas E, Verma A, Chen HL, Gite S, Subashchandrabose P, Dervin S, Schulze K, Darbonne WC, Yun C, Wistuba II, Futreal PA, Woodman SE, Yao JC. Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors: A Nonrandomized Clinical Trial. JAMA Oncol 3(10):1335-1342, 2022. e-Pub 2022. PMID: 35389428.
8. Rogers JE, Woodard TL, Gonzalez GM, Dasari A, Johnson B, Morris VK, Kee B, Vilar E, Nancy You Y, Chang GJ, Bednarski B, Skibber JM, Rodriguez-Bigas MA, Eng C. Colorectal cancer during pregnancy or postpartum. Obstet Med 15(2):118-124, 2022. e-Pub 2021. PMID: 35845232.
9. Erstad DJ, Dasari A, Taggart MW, Kaur H, Konishi T, Bednarski BK, Chang GJ. Prognosis for Poorly Differentiated, High-Grade Rectal Neuroendocrine Carcinomas. Ann Surg Oncol 29(4):2539-2548, 2022. e-Pub 2021. PMID: 34787737.
10. Morris V, Kee B, Overman M, Dasari A, Raghav K, Johnson B, Parseghian C, Wolff RA, Garg N, Eng C, Kopetz S. Clinical and pathologic features correlated with rare favorable survival in patients with BRAFV600E mutated colorectal cancer. J Gastrointest Oncol 13(2):647-656, 2022. PMID: 35557581.
11. Dasari A, Shen C, Devabhaktuni A, Nighot R, Sorbye H. Survival According to Primary Tumor Location, Stage, and Treatment Patterns in Locoregional Gastroenteropancreatic High-grade Neuroendocrine Carcinomas. Oncologist 27(4):299-306, 2022. PMID: 35380711.
12. Taku N, Yi-Qian YN, Chang GJ, Ludmir EB, Raghav KPS, Rodriguez-Bigas MA, Holliday EB, Smith GL, Minsky BD, Overman MJ, Messick C, Boyce-Fappiano D, Koong AC, Skibber JM, Koay EJ, Dasari A, Taniguchi CM, Bednarski BK, Morris VK, Kopetz S, Das P. Benchmarking Outcomes for Definitive Treatment of Young-Onset, Locally Advanced Rectal Cancer. Clin Colorectal Cancer 21(1):e28-e37, 2022. e-Pub 2021. PMID: 34794903.
13. Maliha Nusrat, Muddassir Ali Syed, Riham Katkhuda, edwin R. Parra, Igacio Ivan Wistuba, Paul Kong, Amanda Koehne, Arvind Dasari, Michael J. Overman, David Menter, Scott Kopetz. The immune impact of PI3K-AKT pathway inhibition in colorectal cancer. Journal of Clinical Oncology 40(4):154-154, 2022. e-Pub 2022.
14. Oscar Villarreal, Fadl A. Zeineddine, Ray Chacko, Christine Megerdichian Parseghian, Benny Johnson, Jason Willis, Michael Sangmin Lee, Vaan K. Morris, Arvind Dasari, Kanwal Pratap, Singh Raghav, Michael j. Overman, Y. Nancy You, Yinghong Wang, Dipen M. Maru, John Paul Y.C. Shen, Scott Kopetz. Outcomes of IBD-associated colorectal cancer and implications in early-onset colorectal cancer. Journal of Clinical Oncology 40(4):22-22, 2022. e-Pub 2022.
15. Heloisa P. Soares, Katherine A Guthrie, Syed A. Ahmad, Mary Kay Washington, Brian Hemendra Ramnaraign, Nitya Prabhakar Raj, Carole Seigel, Shay Bellasea, E. Gabriela Chiorean, Arvind Dasari, Jonathan R. Strosberg, Cathy Eng, Philip Agop Philip. Randomized phase II trial of postoperative adjuvant capecitabine and temozolomide versus observation in high-risk pancreatic neuroendocrine tumors: SWOG S2104. Journal of Clinical Oncology 40 40. e-Pub 2022.
16. Arvind Dasari, Yan Lin, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Ibrahim Halil Halil Sahin, Dustin A. Deming, Philip Agop Philip, Theodore S. Hong, Norman Wolmark, Greg Yothers, Thomas J. George, Christopher Hanyoung Lieu. NRG-GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US). Journal of Clinical Oncology 40(4). e-Pub 2022.
17. Arvind Dasari, Joleen M. Hubbard, Cathy Eng, Heather Yeckes-Rodin, Stacey M Ukrainskyj, Zhao Yang, William R. Schelman, Marek K. Kania, Tanios S. Bekaii-Saab. Phase 1/1b trial of fruquintinib in patients with advanced solid tumors: Preliminary results of the dose expansion cohorts in refractory metastatic colorectal cancer. Journal of Clinical Oncology 40(4):93-93, 2022. e-Pub 2022.
18. Arvind Dasari, Maen Abdelrahim, Jared David Acoba, Krishna Chaitanya Alluri, Tornislav Dragovivh, Seyed Mohammad Ali Kazmi, Benjamin Leon Musher, Ryan Sun, Lucas Wong, Y Nancy You, Robert Anthony Zaiden, Scott Kopetz. Minimal residual disease assessment in colorectal cancer (MiRDA-C). Journal of Clinical Oncology 40(4). e-Pub 2022.
19. You YN, Dasari A, Chang GJ. Report from American Society of Clinical Oncology Symposium 2020 and American Society of Clinical Oncology Gastrointestinal Cancer Symposium 2021. Dis Colon Rectum 65(1):8-10, 2022. PMID: 34784317.
20. Rogers JE, Lam M, Halperin DM, Dagohoy CG, Yao JC, Dasari A. Fluorouracil, Doxorubicin with Streptozocin and Subsequent Therapies in Pancreatic Neuroendocrine Tumors. Neuroendocrinology 112(1):34-42, 2022. e-Pub 2021. PMID: 33434908.
21. Honan KA, Hassan S, Deswal A, Herrmann J, Song J, Monlezun D, Halperin D, Mahvash A, Dasari A, Koutroumpakis E, Akay M, Balanescu DV, de Armas IS, Patel M, Nathan S, Kar B, Marmagkiolis K, Lopez-Mattei J, Patel J, Gregoric I, Yao J, Iliescu CA. Bioprosthetic valve monitoring in patients with carcinoid heart disease. Front Cardiovasc Med 9:1072890, 2022. e-Pub 2023. PMID: 36712267.
22. Rogers JE, Woodard TL, Dasari A, Kee B, Das P, Bednarski BK, Skibber JM, Rodriguez-Bigas MA, Eng C. Fertility discussions in young adult stage III colorectal cancer population: a single-center institution experience. Support Care Cancer 29(12):7351-7354, 2021. e-Pub 2021. PMID: 34050401.
23. Fujii Y, Tzeng CW, Chiang YJ, Halperin DM, Dasari A, Kim MP, Katz MHG, Lee JE, Ikoma N. Incidence of Lymph Node Metastases and Impact of Radical Surgery for Duodenal Neuroendocrine Tumors. J Surg Res 268:419-431, 2021. e-Pub 2021. PMID: 34416414.
24. Das S, Du L, Lee CL, Arhin ND, Chan JA, Kohn EC, Halperin DM, Berlin J, LaFerriere H, Singh S, Kunz PL, Dasari A. Comparison of Design, Eligibility, and Outcomes of Neuroendocrine Neoplasm Trials Initiated From 2000 to 2009 vs 2010 to 2020. JAMA Netw Open 4(10):e2131744, 2021. e-Pub 2021. PMID: 34705010.
25. MacFarlane AW, Yeung HM, Alpaugh RK, Dulaimi E, Engstrom PF, Dasari A, Campbell KS, Vijayvergia N. Impacts of pembrolizumab therapy on immune phenotype in patients with high-grade neuroendocrine neoplasms. Cancer Immunol Immunother 70(7):1893-1906, 2021. e-Pub 2021. PMID: 33398390.
26. Raghav K, Anand S, Gothwal A, Singh P, Dasari A, Overman MJ, Loree JM. Underreporting of race/ethnicity in COVID-19 research. Int J Infect Dis 108:419-421, 2021. e-Pub 2021. PMID: 34087489.
27. Arhin ND, Shen C, Bailey CE, Matsuoka LK, Hawkins AT, Holowatyj AN, Ciombor KK, Hopkins MB, Geiger TM, Kam AE, Roth MT, Lebeck Lee CM, Lapelusa M, Dasari A, Eng C. Surgical resection and survival outcomes in metastatic young adult colorectal cancer patients. Cancer Med 10(13):4269-4281, 2021. e-Pub 2021. PMID: 34132476.
28. Advani SM, Swartz MD, Loree J, Davis JS, Sarsashek AM, Lam M, Lee MS, Bressler J, Lopez DS, Daniel CR, Morris V, Shureqi I, Kee B, Dasari A, Vilar E, Overman M, Hamilton S, Maru D, Braithwaite D, Kopetz S. Epidemiology and Molecular-Pathologic Characteristics of CpG Island Methylator Phenotype (CIMP) in Colorectal Cancer. Clin Colorectal Cancer 20(2):137-147.e1, 2021. e-Pub 2020. PMID: 33229221.
29. Shah S, Gosain R, Groman A, Gosain R, Dasari A, Halfdanarson TR, Mukherjee S. Incidence and Survival Outcomes in Patients with Lung Neuroendocrine Neoplasms in the United States. Cancers (Basel) 13(8), 2021. e-Pub 2021. PMID: 33916960.
30. Malakorn S, Ouchi A, Hu CY, Sandhu L, Dasari A, You YN, Kopetz ES, Ellis LM, Chang GJ. Tumor Sidedness, Recurrence, and Survival After Curative Resection of Localized Colon Cancer. Clin Colorectal Cancer 20(1):e53-e60, 2021. e-Pub 2020. PMID: 33004292.
31. Fang L, Arvind D, Dowlati A, Mohamed A. Role of immunotherapy in gastro-enteropancreatic neuroendocrine neoplasms (gep-nens): Current advances and future directions. J Neuroendocrinol 33(3):e12943, 2021. PMID: 33724586.
32. Mendis S, Anand S, Karasinska JM, Dasari A, Unger JM, Gothwal A, Ellis LM, Varadhachary G, Kopetz S, Overman MJ, Raghav K, Loree JM. Sex Representation in Clinical Trials Associated with FDA Cancer Drug Approvals Differs Between Solid and Hematologic Malignancies. Oncologist 26(2):107-114, 2021. e-Pub 2020. PMID: 32960478.
33. Kawaguchi Y, Newhook TE, Tran Cao HS, Tzeng CD, Chun YS, Aloia TA, Dasari A, Kopetz S, Vauthey JN. Alteration of FBXW7 is Associated with Worse Survival in Patients Undergoing Resection of Colorectal Liver Metastases. J Gastrointest Surg 25(1):186-194, 2021. e-Pub 2020. PMID: 33205306.
34. Rogers JE, Lam M, Halperin DM, Dagohoy CG, Yao JC, Dasari A. FAS and Subsequent Therapies in Pancreatic Neuroendocrine Tumors. Neuroendocrinology. e-Pub 2021. PMID: 33434908.
35. Henry JT, Coker O, Chowdhury S, Shen JP, Morris VK, Dasari A, Raghav K, Nusrat M, Kee B, Parseghian C, Pant S, Jeyakumar N, Zhu L, Nishioka Y, Fogelman D, Wolff RA, Hong D, Overman MJ, Vauthey J, Kopetz S, Johnson B. Comprehensive Clinical and Molecular Characterization of KRAS G12C-Mutant Colorectal Cancer. JCO Precis Oncol 5, 2021. e-Pub 2021. PMID: 34250391.
36. Dasari A, Morris VK, Allegra CJ, Atreya C, Benson AB, Boland P, Chung K, Copur MS, Corcoran RB, Deming DA, Dwyer A, Diehn M, Eng C, George TJ, Gollub MJ, Goodwin RA, Hamilton SR, Hechtman JF, Hochster H, Hong TS, Innocenti F, Iqbal A, Jacobs SA, Kennecke HF, Lee JJ, Lieu CH, Lenz HJ, Lindwasser OW, Montagut C, Odisio B, Ou FS, Porter L, Raghav K, Schrag D, Scott AJ, Shi Q, Strickler JH, Venook A, Yaeger R, Yothers G, You YN, Zell JA, Kopetz S. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper. Nat Rev Clin Oncol 17(12):757-770, 2020. e-Pub 2020. PMID: 32632268.
37. Jácome AA, Kee B, Fogelman D, Dasari A, Shureiqi I, Raghav K, Morris V, Johnson B, Overman M, Wolff R, Kopetz S, Rogers J, Ahmed SU, Mehdizadeh A, Rothschild N, Eng C. FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival. Clin Colorectal Cancer 19(4):248-255.e6, 2020. e-Pub 2020. PMID: 32665092.
38. Peacock O, Limvorapitak T, Bednarski BK, Kaur H, Taggart MW, Dasari A, Holliday EB, Minsky BD, You YN, Chang GJ. Robotic lateral pelvic lymph node dissection after chemoradiation for rectal cancer: a Western perspective. Colorectal Dis 22(12):2049-2056, 2020. e-Pub 2020. PMID: 32892473.
39. Peacock O, Limvorapitak T, Hu CY, Bednarski BK, Tillman MM, Kaur H, Taggart MW, Dasari A, Holliday EB, You YN, Chang GJ. Robotic rectal cancer surgery: comparative study of the impact of obesity on early outcomes. Br J Surg 107(12):1552-1557, 2020. e-Pub 2020. PMID: 32996597.
40. Dasari A, Joish VN, Perez-Olle R, Dharba S, Balaji K, Halperin DM. Work productivity burden and indirect costs associated with carcinoid syndrome diarrhea. Expert Rev Pharmacoecon Outcomes Res 20(5):1-5, 2020. e-Pub 2019. PMID: 31448649.
41. Unger JM, Hershman DL, Osarogiagbon RU, Gothwal A, Anand S, Dasari A, Overman M, Loree JM, Raghav K. Representativeness of Black Patients in Cancer Clinical Trials Sponsored by the National Cancer Institute Compared With Pharmaceutical Companies. JNCI Cancer Spectr 4(4):pkaa034, 2020. e-Pub 2020. PMID: 32704619.
42. Bergsland EK, Halperin DM, Dillon JS, Dasari NA, Kunz PL, Soares HP, Pryma D, Bodei L, Hope T, Soulen MC, Mailman J, Howe JR. North American Neuroendocrine Tumor Society Guide for Neuroendocrine Tumor Patient Health Care Providers During COVID-19. Pancreas 49(6):723-728, 2020. PMID: 32433264.
43. Avila S, Chang GJ, Dasari NA, Smani DA, Das P, Herman JM, Koay E, Koong A, Krishnan S, Minsky BD, Smith GL, Taniguchi C, Taggart MW, Kaur H, Holliday EB. Pathologic Response and Postoperative Complications After Short-course Radiation Therapy and Chemotherapy for Patients With Rectal Adenocarcinoma. Clin Colorectal Cancer 19(2):116-122, 2020. e-Pub 2020. PMID: 32173279.
44. Vijayvergia N, Dasari A, Deng M, Litwin S, Al-Toubah T, Alpaugh RK, Dotan E, Hall MJ, Ross NM, Runyen MM, Denlinger CS, Halperin DM, Cohen SJ, Engstrom PF, Strosberg JR. Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials. Br J Cancer 122(9):1309-1314, 2020. e-Pub 2020. PMID: 32152503.
45. Gosain R, Ball S, Rana N, Groman A, Gage-Bouchard E, Dasari A, Mukherjee S. Geographic and demographic features of neuroendocrine tumors in the United States of America: A population-based study. Cancer 126(4):792-799, 2020. e-Pub 2019. PMID: 31714595.
46. Dasari A, Joish VN, Perez-Olle R, Dharba S, Balaji K, Halperin DM. Direct costs of carcinoid syndrome diarrhea among adults in the United States. World J Gastroenterol 25(47):6857, 2019. e-Pub 2019. PMID: 31885426.
47. Loree JM, Anand S, Dasari A, Unger JM, Gothwal A, Ellis LM, Varadhachary G, Kopetz S, Overman MJ, Raghav K. Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018. JAMA Oncol 5(10):e191870, 2019. e-Pub 2019. PMID: 31415071.
48. Malakorn S, Yang Y, Bednarski BK, Kaur H, You YN, Holliday EB, Dasari A, Skibber JM, Rodriguez-Bigas MA, Chang GJ. Who Should Get Lateral Pelvic Lymph Node Dissection After Neoadjuvant Chemoradiation?. Dis Colon Rectum 62(10):1158-1166, 2019. PMID: 31490825.
49. Korphaisarn K, Morris V, Davis JS, Overman MJ, Fogelman DR, Kee BK, Dasari A, Raghav KPS, Shureiqi I, Trupti M, Wolff RA, Eng C, Menter DG, Hamilton S, Kopetz S. Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma. Br J Cancer 121(6):505-510, 2019. e-Pub 2019. PMID: 31406299.
50. Kulke MH, Benson AB, Dasari A, Huynh L, Cai B, Totev T, Roesner N, Duh MS, Neary MP, Maurer VE, Shih BE, Dagohoy CG, Chan J, Bergsland EK. Real-World Treatment Patterns and Clinical Outcomes in Advanced Gastrointestinal Neuroendocrine Tumors (GI NET): A Multicenter Retrospective Chart Review Study. Oncologist 24(8):1056-1065, 2019. e-Pub 2019. PMID: 30606883.
51. Dasari A, Bergsland EK, Benson AB, Cai B, Huynh L, Totev T, Shea J, Duh MS, Neary MP, Dagohoy CG, Shih BE, Maurer VE, Chan J, Kulke MH. Treatment Patterns and Clinical Outcomes in Advanced Lung Neuroendocrine Tumors in Real-World Settings: A Multicenter Retrospective Chart Review Study. Oncologist 24(8):1066-1075, 2019. e-Pub 2019. PMID: 30610008.
52. Adams JR, Ray D, Willmon R, Pulgar S, Dasari A. Living With Neuroendocrine Tumors: Assessment of Quality of Life Through a Mobile Application. JCO Clin Cancer Inform 3:1-10, 2019. PMID: 31283354.
53. Samdani RT, Wasylishen AR, Halperin DM, Dasari A, Yao JC, Rashid A, Estrella JS. Loss of Menin Expression by Immunohistochemistry in Pancreatic Neuroendocrine Tumors: Comparison Between Primary and Metastatic Tumors. Pancreas 48(4):510-513, 2019. PMID: 30946241.
54. Overman MJ, Adam L, Raghav K, Wang J, Kee B, Fogelman D, Eng C, Vilar E, Shroff R, Dasari A, Wolff R, Morris J, Karunasena E, Pisanic TR, Azad N, Kopetz S. Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer. Ann Oncol 30(3):495, 2019. PMID: 29982323.
55. Halperin DM, Lee JJ, Ng CS, Strosberg JR, Estrella JS, Dagohoy CG, Dasari A, Yao JC. A Phase II Trial of Ziv-Aflibercept in Patients With Advanced Pancreatic Neuroendocrine Tumors. Pancreas 48(3):381-386, 2019. PMID: 30768575.
56. Parseghian CM, Loree JM, Morris VK, Liu X, Clifton KK, Napolitano S, Henry JT, Pereira AA, Vilar E, Johnson B, Kee B, Raghav K, Dasari A, Wu J, Garg N, Raymond VM, Banks KC, Talasaz AA, Lanman RB, Strickler JH, Hong DS, Corcoran RB, Overman MJ, Kopetz S. Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. Ann Oncol 30(2):243-249, 2019. PMID: 30462160.
57. Shen C, Gu D, Zhou S, Xu Y, Sarshekeh AM, Halperin D, Shih YT, Yao JC, Dasari A. Racial Differences in the Incidence and Survival of Patients With Neuroendocrine Tumors. Pancreas 48(10):1373-1379, 2019. PMID: 31688604.
58. Johnson B, Loree JM, Jacome AA, Mendis S, Syed M, Morris Ii VK, Parseghian CM, Dasari A, Pant S, Raymond VM, Vilar E, Overman M, Kee B, Eng C, Raghav K, Kopetz S. Atypical, Non-V600 BRAF Mutations as a Potential Mechanism of Resistance to EGFR Inhibition in Metastatic Colorectal Cancer. JCO Precis Oncol 3, 2019. e-Pub 2019. PMID: 32914034.
59. Davis SL, Eckhardt SG, Diamond JR, Messersmith WA, Dasari A, Weekes CD, Lieu CH, Kane M, Choon Tan A, Pitts TM, Leong S. A Phase I Dose-Escalation Study of Linsitinib (OSI-906), a Small-Molecule Dual Insulin-Like Growth Factor-1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced Cancer. Oncologist 23(12):1409-e140, 2018. e-Pub 2018. PMID: 30139840.
60. Shen C, Dasari A, Xu Y, Zhou S, Gu D, Chu Y, Halperin DM, Shih YT, Yao JC. Pre-existing Symptoms and Healthcare Utilization Prior to Diagnosis of Neuroendocrine Tumors: A SEER-Medicare Database Study. Sci Rep 8(1):16863, 2018. e-Pub 2018. PMID: 30442902.
61. Krishnamurthy A, Dasari A, Noonan AM, Mehnert JM, Lockhart AC, Leong S, Capasso A, Stein MN, Sanoff HK, Lee JJ, Hansen A, Malhotra U, Rippke S, Gustafson DL, Pitts TM, Ellison K, Davis SL, Messersmith WA, Eckhardt SG, Lieu CH. Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer. Cancer Res 78(18):5398-5407, 2018. e-Pub 2018. PMID: 30042150.
62. Shen C, Dasari A, Gu D, Chu Y, Zhou S, Xu Y, Halperin D, Fu S, Yao JC, Shih YT. Costs of Cancer Care for Elderly Patients with Neuroendocrine Tumors. Pharmacoeconomics 36(8):1005-1013, 2018. e-Pub 2018. PMID: 29682693.
63. Husnain M, Park W, Ramos JC, Johnson TE, Chan J, Dasari A, Mudad R, Hosein PJ. Complete response to ipilimumab and nivolumab therapy in a patient with extensive extrapulmonary high-grade small cell carcinoma of the pancreas and HIV infection. J Immunother Cancer 6(1):1-5, 2018. e-Pub 2018. PMID: 29986769.
64. Cloyd JM, Omichi K, Mizuno T, Kawaguchi Y, Tzeng CD, Conrad C, Chun YS, Aloia TA, Katz MHG, Lee JE, Halperin D, Yao J, Vauthey JN, Dasari A. Preoperative Fluorouracil, Doxorubicin, and Streptozocin for the Treatment of Pancreatic Neuroendocrine Liver Metastases. Ann Surg Oncol 25(6):1709-1715, 2018. e-Pub 2018. PMID: 29626307.
65. Loree JM, Pereira AAL, Lam M, Willauer AN, Raghav K, Dasari A, Morris VK, Advani S, Menter DG, Eng C, Shaw K, Broaddus R, Routbort MJ, Liu Y, Morris JS, Luthra R, Meric-Bernstam F, Overman MJ, Maru D, Kopetz S. Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and Consensus Molecular Subtypes. Clin Cancer Res 24(5):1062-1072, 2018. e-Pub 2017. PMID: 29180604.
66. Dasari A, Mehta K, Byers LA, Sorbye H, Yao JC. Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases. Cancer 124(4):807-815, 2018. e-Pub 2017. PMID: 29211313.
67. Overman MJ, Adam L, Raghav K, Wang J, Kee B, Fogelman D, Eng C, Vilar E, Shroff R, Dasari A, Wolff R, Morris J, Karunasena E, Pisanic TR, Azad N, Kopetz S. Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer. Ann Oncol 29(1):139-144, 2018. e-Pub 2017. PMID: 29069279.
68. Shen C, Chu Y, Halperin DM, Dasari A, Zhou S, Xu Y, Yao JC, Shih YT. Carcinoid Syndrome and Costs of Care During the First Year After Diagnosis of Neuroendocrine Tumors Among Elderly Patients. Oncologist 22(12):1451-1462, 2017. e-Pub 2017. PMID: 28642335.
69. Mehrvarz Sarshekeh A, Advani S, Halperin DM, Conrad C, Shen C, Yao JC, Dasari A. Regional lymph node involvement and outcomes in appendiceal neuroendocrine tumors: a SEER database analysis. Oncotarget 8(59):99541-99551, 2017. e-Pub 2017. PMID: 29245922.
70. Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients with Neuroendocrine Tumors in the United States. JAMA Oncol 3(10):1335-1342, 2017. e-Pub 2017. PMID: 28448665.
71. Parseghian CM, Parikh NU, Wu JY, Jiang ZQ, Henderson L, Tian F, Pastor B, Ychou M, Raghav K, Dasari A, Fogelman DR, Katsiampoura AD, Menter DG, Wolff RA, Eng C, Overman MJ, Thierry AR, Gallick GE, Kopetz S. Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer. Clin Cancer Res 23(15):4146-4154, 2017. e-Pub 2017. PMID: 28280091.
72. Shen C, Dasari A, Chu Y, Halperin DM, Zhou S, Xu Y, Shih YT, Yao JC. Clinical, pathological, and demographic factors associated with development of recurrences after surgical resection in elderly patients with neuroendocrine tumors. (*Both authors contributed equally). Ann Oncol 28(7):1582-1589, 2017. PMID: 28444105.
73. Korphaisarn K, Morris VK, Overman MJ, Fogelman DR, Kee BK, Raghav KPS, Manuel S, Shureiqi I, Wolff RA, Eng C, Menter D, Hamilton SR, Kopetz S, Dasari A. FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma. Oncotarget 8(24):39268-39279, 2017. PMID: 28424412.
74. Halperin DM, Shen C, Dasari A, Xu Y, Chu Y, Zhou S, Shih YT, Yao JC. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol 18(4):525-534, 2017. e-Pub 2017. PMID: 28238592.
75. Roland CL, Starker LF, Kang Y, Chatterjee D, Estrella J, Rashid A, Katz MH, Aloia TA, Lee JE, Dasari A, Yao JC, Fleming JB. Loss of DPC4/SMAD4 expression in primary gastrointestinal neuroendocrine tumors is associated with cancer-related death after resection. Surgery 161(3):753-759, 2017. e-Pub 2016. PMID: 27816207.
76. Mehrvarz Sarshekeh A, Advani S, Overman MJ, Manyam G, Kee BK, Fogelman DR, Dasari A, Raghav K, Vilar E, Manuel S, Shureiqi I, Wolff RA, Patel KP, Luthra R, Shaw K, Eng C, Maru DM, Routbort MJ, Meric-Bernstam F, Kopetz S. Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer. PLoS One 12(5):e0173345, 2017. e-Pub 2017. PMID: 28267766.
77. Prakash L, Bhosale P, Cloyd J, Kim M, Parker N, Yao J, Dasari A, Halperin D, Aloia T, Lee JE, Vauthey JN, Fleming JB, Katz MH. Role of Fluorouracil, Doxorubicin, and Streptozocin Therapy in the Preoperative Treatment of Localized Pancreatic Neuroendocrine Tumors. J Gastrointest Surg 21(1):155-163, 2017. e-Pub 2016. PMID: 27634306.
78. Conrad C, Kutlu OC, Dasari A, Chan JA, Vauthey JN, Adams DB, Kim M, Fleming JB, Katz MH, Lee JE. Prognostic Value of Lymph Node Status and Extent of Lymphadenectomy in Pancreatic Neuroendocrine Tumors Confined To and Extending Beyond the Pancreas. J Gastrointest Surg 20(12):1966-1974, 2016. e-Pub 2016. PMID: 27714644.
79. Rudek MA, Dasari A, Laheru D, He P, Jin R, Walker R, Taylor GE, Jimeno A, Donehower RC, Hidalgo M, Messersmith WA, Purcell WT. Phase I study of ABT-751 in combination with CAPIRI (capecitabine and irinotecan) and bevacizumab in patients with advanced colorectal cancer (*Both authors contributed equally). J Clin Pharmacol 56(8):966-73, 2016. e-Pub 2016. PMID: 26632033.
80. Conte B, George B, Overman M, Estrella J, Jiang ZQ, Mehrvarz Sarshekeh A, Ferrarotto R, Hoff PM, Rashid A, Yao JC, Kopetz S, Dasari A. High Grade Neuroendocrine Colorectal Carcinomas: A Retrospective Study of 100 Patients. Clin Colorectal Cancer 15(2):e1-7, 2016. e-Pub 2015. PMID: 26810202.
81. Overman MJ, Morris V, Kee B, Fogelman D, Xiao L, Eng C, Dasari A, Shroff R, Mazard T, Shaw K, Vilar E, Raghav K, Shureiqi I, Liang L, Mills GB, Wolff RA, Hamilton S, Meric-Bernstam F, Abbruzzese J, Morris J, Maru D, Kopetz S. Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials. Ann Oncol 27(6):1068-74, 2016. e-Pub 2016. PMID: 27045102.
82. Rogers JE, Dasari A, Eng C. The Treatment of Colorectal Cancer During Pregnancy: Cytotoxic Chemotherapy and Targeted Therapy Challenges. Oncologist 21(5):563-70, 2016. e-Pub 2016. PMID: 27000464.
83. Mehrvarz Sarshekeh A, Halperin DM, Dasari A. Update on management of midgut neuroendocrine tumors. Int J Endocr Oncol 3(2):175-189, 2016. e-Pub 2016. PMID: 27347369.
84. Shen C, Xu Y, Dasari A, Shih YC, Yao JC. Octreotide LAR Dosage and Survival Among Elderly Patients With Distant-Stage Neuroendocrine Tumors. Oncologist 21(3):308-313, 2016. e-Pub 2016. PMID: 26911407.
85. Kopetz S, Desai J, Chan E, Hecht JR, O'Dwyer PJ, Maru D, Morris V, Janku F, Dasari A, Chung W, Issa JP, Gibbs P, James B, Powis G, Nolop KB, Bhattacharya S, Saltz L. Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer. J Clin Oncol 33(34):4032, 2015. e-Pub 2015. PMID: 26460303.
86. Dasari A, Phan A, Gupta S, Rashid A, Yeung SC, Hess K, Chen H, Tarco E, Chen H, Wei C, Anh-Do K, Halperin D, Meric-Bernstam F, Yao J. Phase I study of the anti-IGF1R antibody cixutumumab with everolimus and actreotide in advanced well differentiated neuroendocrine tumors. Endocr Relat Cancer 22(15):0002, 2015. e-Pub 2015. PMID: 25900182.
87. Morelli MP, Overman MJ, Dasari A, Kazmi SMA, Mazard T, Vilar E, Morris VK, Lee MS, Herron D, Eng C, Morris J, Kee BK, Janku F, Deaton FL, Garrett C, Maru D, Diehl F, Angenendt P, Kopetz S. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Ann Oncol 26(4):731-6, 2015. e-Pub 2015. PMID: 25628445.
88. Messersmith WA, Shapiro GI, Cleary JM, Jimeno A, Dasari A, Huang B, Shaik MN, Cesari R, Zheng X, Reynolds JM, English PA, McLachlan KR, Kern KA, LoRusso PM. A phase I dosing finding study in patients with advanced solid malignancies of the oral y-secretase inhibitor PF-03084014. Clin Cancer Res 21(1):60-7, 2015. e-Pub 2014. PMID: 25231399.
89. Morris V, Overman MJ, Jiang ZQ, Garrett C, Agarwal S, Eng C, Kee B, Fogelman D, Dasari A, Wolff R, Maru D, Kopetz S. Progression-Free Survival Remains Poor Over Sequential Lines of Systemic Therapy in Patients With BRAF-Mutated Colorectal Cancer. Clin Colorectal Cancer 13(3):164-71, 2014. e-Pub 2014. PMID: 25069797.
90. De Jesus-Acosta A, Laheru D, Maitra A, Arcaroli J, Rudek MA, Dasari A, Blatchford PJ, Quackenbush K, Messersmith W. A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma. Invest New Drugs 32(4):739-45, 2014. e-Pub 2014. PMID: 24668033.
91. Rogers JE, Ohinata A, Dasari A, Eng C. Atypical metastatic presentations in colorectal cancer: a case series. Clin Colorectal Cancer 13(1):e1-e4, 2014. e-Pub 2013. PMID: 24342822.
92. Azad N, Dasari A, Arcaroli J, Taylor GE, Laheru DA, Carducci MA, McManus M, Quackenbush K, Wright JJ, Hidalgo M, Diaz LA, Donehower RC, Zhao M, Rudek MA, Messersmith WA. Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer. (*Both authors contributed equally). Invest New Drugs 31(2):345-54, 2013. e-Pub 2012. PMID: 22615057.
93. Dasari A, Gore L, Messersmith WA, Diab S, Jimeno A, Weekes CD, Lewis KD, Drabkin HA, Flaig TW, Camidge DR. A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer. Invest New Drugs 31(1):115-25, 2013. e-Pub 2012. PMID: 22415798.
94. Arcaroli J, Quackenbush K, Dasari A, Powell R, McManus M, Tan AC, Foster NR, Picus J, Wright J, Nallapareddy S, Erlichman C, Hidalgo M, Messersmith WA. Biomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreatic cancer. Cancer Med 1(2):207-17, 2012. e-Pub 2012. PMID: 23342270.
95. Tolcher AW, Messersmith WA, Mikulski SM, Papadopoulos KP, Kwak EL, Gibbon DG, Patnaik A, Falchook GS, Dasari A, Shapiro GI, Boylan JF, Xu ZX, Wang K, Koehler A, Song J, Middleton SA, Deutsch J, Demario M, Kurzrock R, Wheler JJ. Phase I Study of RO4929097, a Gamma Secretase Inhibitor of Notch Signaling, in Patients With Refractory Metastatic or Locally Advanced Solid Tumors. J Clin Oncol 30(19):2348-53, 2012. e-Pub 2012. PMID: 22529266.
96. Arcaroli JJ, Powell RW, Varella-Garcia M, McManus M, Tan AC, Quackenbush KS, Pitts TM, Gao D, Spreafico A, Dasari A, Touban BM, Messersmith WA. ALDH+ tumor-initiating cells that exhibit a gain in notch1 gene copy number have enhanced sensitivity to a γ-secretase inhibitor + irinotecan in colorectal cancer (CRC). Mol Oncol 6(3):370-81, 2012. e-Pub 2012. PMID: 22521243.
97. Arcaroli JJ, Quackenbush KS, Powell RW, Pitts TM, Spreafico A, Varella-Garcia M, Bemis L, Tan AC, Reinemann JM, Touban BM, Dasari A, Eckhardt SG, Messersmith WA. Common PIK3CA mutants and a novel 3'UTR mutation are associated with increased sensitivity to saracatinib. Clin Cancer Res 18(9):2704-14, 2012. PMID: 22553375.
98. Dasari A, Bartholomew JN, Volonte D, Galbiati F. Oxidative stress induces premature senescence by stimulating caveolin-1 gene transcription through p38 mitogen-activated protein kinase/Sp1-mediated activation of two GC-rich promoter elements. Cancer Res 66(22):10805-14, 2006. PMID: 17108117.

Invited Articles

1. Bent A, Raghavan S, Dasari A, Kopetz S. The Future of ctDNA-Defined Minimal Residual Disease: Personalizing Adjuvant Therapy in Colorectal Cancer. Clin Colorectal Cancer 21(2):89-95, 2022. e-Pub 2022. PMID: 35450837.
2. Mohamed A, Asa SL, McCormick T, Al- Shakhshit H, Dasari A, Mauricio R, Salem I, Ocuin LM, Bajor D, .Lee RT, J, Selfridge, Kardan A, Lee Z, Avril N, Kopp S, Winter JM, Hardacre J, Ammori JB, Ghannoum MA. The Role of the Microbiome in Gastroentero-Pancreatic Neuroendocrine Neoplasms (GEP-NENs). Current Issues in Molecular biology(3):1335-1342, 2022. e-Pub 2022.
3. Rogers JE, Dasari A. Pharmacotherapy for unresectable metastatic colorectal cancer. Expert Opin Pharmacother 23(2):1-10, 2022. e-Pub 2021. PMID: 34534031.
4. Eng C, Chen EY, Rogers J, Lewis M, Strosberg J, Thota R, Krishnamurthi S, Oberstein P, Govindarajan R, Buchschacher G, Patel S, Sohal D, Al-Toubah T, Philip P, Dasari A, Kennecke H, Stein S. Moving Beyond the Momentum: Innovative Approaches to Clinical Trial Implementation. JCO Oncol Pract 17(10):OP2000701, 2021. e-Pub 2021. PMID: 33534616.
5. Dasari A, Sobrero A, Yao J, Yoshino T, Schelman W, Yang Z, Chien C, Kania M, Tabernero J, Eng C. FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer. Future Oncol 17(24):3151-3162, 2021. e-Pub 2021. PMID: 33993740.
6. Das S, Dasari A. Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences?. Curr Oncol Rep 23(4):43, 2021. e-Pub 2021. PMID: 33719003.
7. Fang L, Dasari A, Dowlati A, Mohamed A. Role of immunotherapy in gastro-enteropancreatic neuroendocrine neoplasms (gep-nens): Current advances and future directions. J Neuroendocrinol 33(3):e12943, 2021. e-Pub 2021.
8. Das S, Dasari A. Novel therapeutics for patients with well-differentiated gastroenteropancreatic neuroendocrine tumors. Ther Adv Med Oncol 13:17588359211018047, 2021. e-Pub 2021. PMID: 34093744.
9. Kanikarla Marie P, Fowlkes NW, Afshar-Kharghan V, Martch SL, Sorokin A, Shen JP, Morris VK, Dasari A, You N, Sood AK, Overman MJ, Kopetz S, Menter DG. The Provocative Roles of Platelets in Liver Disease and Cancer. Front Oncol 11:643815, 2021. e-Pub 2021. PMID: 34367949.
10. Aapro M, Bossi P, Dasari A, Fallowfield L, Gascón P, Geller M, Jordan K, Kim J, Martin K, Porzig S. Digital health for optimal supportive care in oncology: benefits, limits, and future perspectives. Support Care Cancer 28(10):4589-4612, 2020. e-Pub 2020. PMID: 32533435.
11. George TJ, Franke AJ, Chakravarthy AB, Das P, Dasari A, El-Rayes BF, Hong TS, Kinsella TJ, Landry JC, Lee JJ, Monjazeb AM, Jacobs SA, Raben D, Rahma OE, Williams TM, Wu C, Coleman CN, Vikram B, Ahmed MM. National Cancer Institute (NCI) state of the science: Targeted radiosensitizers in colorectal cancer. Cancer 125(16):2732-2746, 2019. e-Pub 2019. PMID: 31017664.
12. Balanescu DV, Donisan T, Lopez-Mattei J, Hassan S, Kim P, Dasari A, Halperin D, Yao J, Kar B, Gregoric I, Balanescu SM, Iliescu C. The 1, 2, 3, 4 of carcinoid heart disease: Comprehensive cardiovascular imaging is the mainstay of complex surgical treatment. Oncol Lett 17(5):4126-4132, 2019. e-Pub 2018. PMID: 30944605.
13. Hassan SA, Banchs J, Iliescu C, Dasari A, Lopez-Mattei J, Yusuf SW. Carcinoid heart disease. Heart 103(19):1488-1495, 2017. e-Pub 2017. PMID: 28596302.
14. Halperin DM, Dasari A, Yao JC. Future Directions in the Biology of Neuroendocrine Tumors. Pancreas 45(6):783-5, 2016. PMID: 27295529.
15. Halperin DM, Dasari A, Yao JC. [177Lu-DOTA0,Tyr3]-octreotate in the treatment of midgut neuroendocrine tumors. Future Oncol 12(3):313-21, 2016. e-Pub 2016. PMID: 26759064.
16. Dasari A, Yao J. Initial treatment of well differentiated neuroendocrine tumors. Oncology (Williston Park) 28(11):945-7, 2014. PMID: 25741544.
17. Dasari A and Messersmith WA. Are additional clinical trials of adjuvant Bevacizumab therapy indicated in colon cancer?. Current Colorectal Cancer Reports 7(3), 2011.
18. Arcaroli JJ, Dasari A, Messersmith WA, Jimeno A. Gamma secretase inhibitors in solid tumor malignancies. Drugs of the Future 36(9):677, 2011.
19. Dasari A, McCarter M, McManus MC, Russ P, Messersmith WA. Recurrent pancreatic adenocarcinoma after pancreatic resection. Oncology (Williston Park) 24(14):1329-34, 2010. PMID: 21294478.
20. Dasari A, Messersmith WA. New strategies in colorectal cancer: biomarkers of response to epidermal growth factor receptor monoclonal antibodies and potential therapeutic targets in phosphoinositide 3-kinase and mitogen-activated protein kinase pathways. Clin Cancer Res 16(15):3811-8, 2010. e-Pub 2010. PMID: 20554751.

Manuals, Teaching Aids, Other Teaching Publications

1. . Chapter on Gastrointestinal Cancers: ASCO-Self Evaluation Program (ASCO-SEP), 2022.

Other Articles

1. Shirali AS, Pieterman CRC, Lewis MA, Hyde SM, Makawita S, Dasari A, Thosani N, Ikoma N, McCutcheon IE, Waguespack SG, Perrier ND It's not a mystery, it's in the history: Multidisciplinary management of multiple endocrine neoplasia type 1. CA Cancer J Clin 71(5):369-380, 2021. PMID: 34061974.
2. Dasari A, Grothey A, Kopetz S Circulating Tumor DNA-Defined Minimal Residual Disease in Solid Tumors: Opportunities to Accelerate the Development of Adjuvant Therapies. J Clin Oncol 36(35):JCO2018789032. PMID: 30376428.
3. Harry BL, Smith ML, Burton JR, Dasari A, Eckhardt SG, Diamond JR Medullary thyroid cancer and pseudocirrhosis: case report and literature review. Curr Oncol 19(1):e36-41, 2012. PMID: 22328846.

Editorials

1. Strosberg JR, El-Haddad G, Al-Toubah T, Reidy D, Ziv E, Mahvash A, Dasari A, Philip P, Soulen MC. Radioembolization Versus Bland or Chemoembolization for Liver-Dominant Neuroendocrine Tumors: Is it an Either/Or Question?. J Nucl Med 62(12):1669-71. PMID: 34556527.
2. Morris V, Dasari A, Kopetz S. Can Circulating Tumor DNA in Early-Stage Colorectal Cancer Be More Than a Prognostic Biomarker?. JAMA Oncol 5(8):1101-1103, 2019. PMID: 31070713.
3. Halperin DM, Yao JC, Dasari A. What's in a Name? Steady Progress in Staging Pancreatic Neuroendocrine Tumors. J Clin Oncol 35(3):265-267, 2017. PMID: 27893328.
4. Dasari A, Yao JC. Gastrointestinal neuroendocrine tumors: slow but steady progress. Oncology (Williston Park) 28(9):762-3, 2014. PMID: 25224473.

Abstracts

1. J. K. Park Nothing to disclose. K. A. Honan Nothing to disclose. D. J. Monlezun Nothing to disclose. S. Z. Khalaf Nothing to disclose. S. Hassan Nothing to disclose. I. R. Hamzeh Nothing to disclose. J. Song Nothing to disclose. A. Dasari Nothing to disclose. J. Yao Nothing to disclose. K. Charitakis Nothing to disclose. K. Marmagkiolis Nothing to disclose. M. Cilingiroglu Nothing to disclose. A. Deswal Nothing to disclose. C. A. Iliescu. D-42 j Impact of Body Mass Index on Long-Term Mortality in Patients Undergoing Transcatheter Mitral Valve Replacement: A Systematic Review and MetaAnalysis. Journal of the Society for Cardiovascular Angiography & Interventions 2, 2023.
2. 106. Cathy Eng, Arvind Dasari, Sara Lonardi, Rocio Garcia-Carbonero, Elena Elez, Takayuki Yoshino, Alberto F. Sobrero, James C. Yao, Pilar Garcia-Alfonso, Judit Kocsis, Antonio Cubillo, Andrea Sartore-Bianchi, Taroh Satoh, Violaine Randrian, Jiri Tomasek, Geoff Chong, Zhao Yang, Ferdinand M. Guevara, William R. Schelman, Josep Tabernero.. Analysis of fruquintinib adverse events of special interest from phase 3 of the FRESCO-2 study. Journal of Clinical Oncology 41(16):3601-3601. e-Pub 2023.
3. Jesse Joshua Smith, Arvind Dasari, Qian Shi, Julio Garcia-Aguilar, Hanna Kelly Sanoff, Thomas J. George, Theodore S. Hong, Greg Yothers, Philip Agop Philip, Garth D. Nelson, Tareq Al Baghdadi, Olatunji B. Alese, Eileen Mary O'Reilly, Jeffrey A. Meyerhardt, Ardaman Shergill, Natally Horvat, Paul Bernard Romesser, William A. Hall.. A randomized phase II trial testing the efficacy of triplet versus doublet chemotherapy to achieve clinical complete response in patients with locally advanced rectal cancer. Journal of Clinical Oncology 41(16):TPS3640-TPS3640, 2023.
4. Arvind Dasari, Sara Lonardi, Rocio Garcia-Carbonero, Elena Elez, Takayuki Yoshino, Alberto F. Sobrero, James C. Yao, Pilar Garcia-Alfonso, Judit Kocsis, Antonio Cubillo, Andrea Sartore-Bianchi, Taroh Satoh, Violaine Randrian, Jiri Tomasek, Geoff Chong, Zhao Yang, Rajash Pallai, Iris Carton, Josep Tabernero, Cathy Eng. Subgroup analyses of safety and efficacy by number and types of prior lines of treatment in FRESCO-2, a global phase III study of fruquintinib in patients with refractory metastatic colorectal cancer. Journal of Clinical Oncology 41(16):3604-3604, 2023.
5. Arvind Dasari, Alisha Heather Bent, Kristin Alfaro-Munoz, Ryan W Huey, Benny Johnson, Michael Sangmin Lee, Maria Pia Morelli, Van K. Morris, Michael J. Overman, Christine Megerdichian Parseghian, Kanwal Pratap Singh Raghav, John Shen, Jason Willis, Timothy E. Newhook, Abhineet Uppal, Y. Nancy You, Tsuyoshi Konishi, George J. Chang, Scott Kopetz, Robert A. Wolff, MD Anderson INTERCEPT. Association of positive ctDNA-based minimal residual disease assays during surveillance and undiagnosed concomitant radiographic recurrences in colorectal cancer (CRC): Results from the MD Anderson INTERCEPT program. Journal of Clinical Oncology 41(16):3522-3522, 2023.
6. Fadl A. Zeineddine, Mohammad A. Zeineddine, Abdelrahman Yousef, Yue Gu, Saikat Chowdhury, Arvind Dasari, Ryan W. Huey, Benny Johnson, Bryan Kee, Michael S. Lee, Maria Pia Morelli, Van K. Morris, Michael J. Overman, Christine Parseghian, Kanwal Raghav, Jason Willis, Robert A. Wolff, Yoshikuni Kawaguchi, Jean-Nicolas Vauthey, Ryan Sun, Scott Kopetz & John Paul Shen. Survival improvement for patients with metastatic colorectal cancer over twenty years. NPJ Precision Oncology, 2023. e-Pub 2023.
7. Erstad, D. J., Dasari, A., Taggart, M. W., Kaur, H., Konishi, T., Bednarski, B. K., & Chang, G. J.. ASO Visual Abstract: Prognosis for Poorly Differentiated High-Grade Rectal Neuroendocrine Carcinomas. Annals of surgical oncology(1-1), 2022.
8. Van K. Morris, Christine Megerdichian Parseghian, Michelle Escano, Benny Johnson, Kanwal Pratap Singh Raghav, Arvind Dasari, Ryan Huey, Michael J. Overman, Jason Willis, Michael Sangmin Lee, Robert A. Wolff, Bryan K. Kee, John Paul Y.C. Shen, Maria Pia Morelli, Alda Tam, Wai Chin Foo, Lianchun Xiao, Scott Kopetz. Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, BRAFV600E metastatic colorectal cancer. Journal of Clinical Oncology 40 40(4):12-12, 2022. e-Pub 2022.
9. Dasari, A., Paulson, S., Sung, M., Tucci, C., Kauh, J., Kania, M., & Li, D.. Efficacy of Surufatinib in Western Patients (pts) with Pancreatic Neuroendocrine Tumors (PanNETs). Paper presented at the Neuroendocrinology, 2022.
10. Fujii, Y., Tzeng, C., Chiang, Y., Halperin, D., Dasari, A., Kim, M., Katz, M., Lee, J., & Ikoma, N.. Survival impact of incidence of lymph node metastases and radical resection for duodenal neuroendocrine tumors. analyses of the national cancer database, 2021.
11. Kunz, P., Honeycutt, H., Ward, P., & Dasari, A. PCN236 A Retrospective Real-World Evidence Study of Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETS) in the US Using the Optum Database. Value in Health 24(2021):s64, 2021.
12. 23. Mendis, S., Anand, S., Karasinska, J. M., Dasari, A., Unger, J. M., Gothwal, A., Ellis, L. M., Varadhachary, G., Kopetz, S., & Overman, M. J. Sex representation in clinical trials associated with FDA cancer drug approvals differs between solid and hematologic malignancies. The Oncologist 26(2):107-114, 2021.
13. Gouda, M., Overman, M., Huang, H., Thomas, J., Dasari, N., Meric-Bernstam, F., Kopetz, S., & Janku, F. 91P Liquid biopsy for detection of minimal residual disease after liver metastasectomy in stage IV colorectal cancer. Annals of Oncology 32:s395-s396, 2021.
14. Kunz, P., Honeycutt, H., Ward, P., & Dasari, A.. PCN236 A Retrospective Real-World Evidence Study of Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETS) in the US Using the Optum Database. Value in Health 24(s64), 2021.
15. Shah, S., Gosain, R., Groman, A., Gosain, R., Dasari, A., Halfdanarson, T. R., & Mukherjee, S. Incidence and survival outcomes in patients with lung neuroendocrine neoplasms in the united states. Cancers, 13(8):1753, 2021.
16. Shah, S., Gosain, R., Groman, A., Gosain, R., Dasari, A., Halfdanarson, T., & Mukherjee, S.. Trends in the Incidence and Survival Outcomes in Patients With Lung Neuroendocrine Neoplasms in the United States. Paper presented at the Pancreas, 2021.
17. 19. Dasari, N., Wang-Gillam, A., Hubbard, J., Fernandez, A., Nanda, S., Kania, M., Schelman, W., & Bekaii-Saab, T.. 458P Phase (Ph) I/Ib trial of fruquintinib (fru) in patients (pts) with advanced solid tumors: Preliminary results of the dose expansion (exp) cohort in refractory metastatic colorectal cancer (mCRC). Annals of Oncology 31:S436-S437, 2020.
18. 13. Dasari, A., Joish, V., Perez-Olle, R., Dharba, S., Balaji, K., & Halperin, D.. PCN113 Direct and indirect costs associated with carcinoid syndrome diarrhea. Value in Health 22:s77, 2019.
19. Halperin, D. M., Lee, J. J., Ng, C. S., Strosberg, J. R., Estrella, J. S., Dagohoy, C. G., Dasari, A., & Yao, J. C. A phase II trial of ziv-aflibercept in patients with advanced pancreatic neuroendocrine tumors. Pancreas 48(3):381-386, 2019.
20. Hamilton, E., Wang, J., Li, D., Dasari, N., Paulson, S., Cohn, A., Sauter, N., Kania, M., Kauh, J., & Falchook, G.. Safety and tolerability of surufatinib in western patients with solid tumours. Annals of Oncology:v569-v570, 2019.
21. 16. Kulke, M. H., Benson, A. B., Dasari, A., Huynh, L., Cai, B., Totev, T., Roesner, N., Duh, M. S., Neary, M. P., & Maurer, V. E. Real‐World Treatment Patterns and Clinical Outcomes in Advanced Gastrointestinal Neuroendocrine Tumors (GI NET):. A Multicenter Retrospective Chart Review Study. The Oncologist 24(8):1056-1065, 2019.
22. Samdani, R. T., Wasylishen, A. R., Halperin, D. M., Dasari, A., Yao, J. C., Rashid, A., & Estrella, J. S.. Loss of Menin expression by immunohistochemistry in pancreatic neuroendocrine tumors: comparison between primary and metastatic tumors. Pancreas 48(4):510-513, 2019.
23. Adams, J., Ray, D., Willmon, R., Gautam, A., Pulgar, S., & Dasari, A.. Living With Neuroendocrine Tumors: Assessing Quality of Life (QoL) Through a Mobile Application. Paper presented at the Pancreas, 2019.
24. Dasari, A., Bergsland, E. K., Benson, A. B., Cai, B., Huynh, L., Totev, T., Shea, J., Duh, M. S., Neary, M. P., & Kulke, M. H.. Real-world Analysis of Long-Term Treatment Patterns and Clinical Outcomes Among Patients With Advanced Neuroendocrine Tumors of Lung Origin: A Multicenter Study. Paper presented at the Pancreas, 2019.
25. Kulke, M. H., Benson, A. B., Dasari, A., Huynh, L., Cai, B., Totev, T., Roesner, N., Duh, M. S., Neary, M. P., & Bergsland, E. K.. Real-world Analysis of Long-Term Treatment Patterns in Patients With Advanced Gastrointestinal Neuroendocrine Tumors (GI NET). A Multicenter Study. Paper presented at the Pancreas, 2019.
26. Lam, M., Rogers, J., Halperin, D., Dagohoy, C., Yao, J., & Dasari, A.. Outcomes with 5-Fluorouracil, Doxorubicin, and Streptozocin (FAS) and subsequent therapies in patients with well differentiated Pancreatic Neuroendocrine Tumors (PanNETs. Paper presented at the Pancreas, 2019.
27. Yeung, H., Macfarlane, A., Campbell, K., Ruth, K., Gong, Y., Engstrom, P., Dasari, A., & Vijayvergia, N. Characterizing Immunophenotyping Changes with Pembrolizumab (P) Therapy in Grade 3 Neuroendocrine Neoplasms (G3 NENs). Paper presented at the Neuroendocrinology, 2019.
28. Dasari A, Halperin D, Coya T, Zorrilla I, Meric-Bernstam F, Yao J. A Pilot Study of the Cyclin Dependent Kinases 4, 6 Inhibitor Ribociclib in Patients with Foregut Neuroendocrine Tumors. NANETS 2018 Symposium, 2018.
29. Vijayvergia N, Dasari A, Ross EA, Dotan E, Halperin DM, Astsaturov IA, Hall MJ, Ross NM, McClean D, Denlinger CS, Cohen SJ, Engstrom PF. Pembrolizumab (P) monotherapy in patients with previously treated metastatic high grade neuroendocrine neoplasms (HG-NENs). J Clin Oncol 36(Suppl), 2018.
30. Cruz A, Uraoka N, Cuentas ERP, Solis LM, Dasari A, Overman MJ, Loree JM, Yao JC, Wistuba II, Halperin DM, Estrella J. Prognostic significance of tumor-associated macrophages in pancreatic neuroendocrine tumors. J Clin Oncol 36(Suppl), 2018.
31. Vijayvergia N, Dasari A, Ross EA, Ruth K, Litwin S, Dotan E, Halperin DM, Astsaturov IA, Hall MJ, Ross NM, McClean D, Denlinger CS, Cohen SJ, Engstrom PF. Pembrolizumab (P) monotherapy in patients with previously treated metastatic high grade neuroendocrine neoplasms (HG-NENs). NANETS 2018 Symposium, 2018.
32. 11. Dasari, A., Bergsland, E., Benson, A., Cai, B., Huynh, L., Totev, T., Shea, J., Duh, M., Neary, M., & Kulke, M.. Real-World Analysis of Treatment Patterns and Long-Term Effectiveness Among Patients with Advanced Neuroendocrine Tumors of Lung Origin (Lung Net). A Multicenter Study. Value in Health 21:s11, 2018.
33. Huynh, L., Totev, T., Dasari, A., Bergsland, E. K., Benson III, A. B., Cai, B., Shea, J., Duh, M. S., Neary, M. P., & Kulke, M. H.. Real-world analysis of treatment patterns and long-term effectiveness among patients with advanced neuroendocrine tumors of lung origin: A multicenter study. Paper presented at the PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018.
34. Sarshekeh, A. M., Advani, S., Halperin, D. M., Conrad, C., Shen, C., Yao, J. C., & Dasari, A. Regional lymph node involvement and outcomes in appendiceal neuroendocrine tumors: a SEER database analysis. Paper presented at the Pancreas, 2018.
35. Chun YS, Mehran RJ, Tzeng CD, Kee BK, Dasari NA, Sepsesi B, Conrad C, Aloia TA, Kopetz S, Vauthey JN,. LUNA: A randomized phase II trial of liver resection plus chemotherapy or chemotherapy alone in patients with unresectable lung and resectable liver meastases from colorectal adenocarcinoma. J Clin Oncol, 2017.
36. Shen C, Chu Y, Dasari A, Zhou S, Halperin DM, Xu Y, Shih YT, Yao JC. Pre-existing symptoms, resource utilization, and healthcare costs prior to diagnosis of neuroendocrine tumors: A SEER-Medicare database study. J Clin Oncol, 2017.
37. Krishnamurthy A, Dasari A, Noonan AM, Mehnert JM, Lockhart AC, Stein MN, Sanoff HK, Lee JJ, Hansen AR, Malhotra U, Rippke S, Davis SL, Messersmith WA, Eckhardt SG, Lieu CH. A phase IB study of the combination of selumetinib (AZD6244, ARRY-142886) and cyclosporin A (CsA) in patients with advanced solid tumors with an expansion cohort in metastatic colorectal cancer (mCRC). J Clin Oncol, 2017.
38. Dasari A, Shen C, Chu Y, Halperin DM, Xu Y, Zhou S, Shih T, Yao JC. Prevalence of co-morbidities in elderly patients with distant stage neuroendocrine tumors. J Clin Oncol, 2017.
39. Conrad, C., Kutlu, O., Dasari, A., & Lee, J.. The Prognostic Value of Lymph Node Status and Extent of Lymphadenectomy in Pancreatic Neuroendocrine Tumors Confined To and Extending Beyond the Pancreas, 2017.
40. Dasari, A., Mehta, K., Sorbye, H., & Yao, J. Gastroenteropancreatic high-grade neuroendocrine carcinomas: a SEER database analysis of 6291 cases. Paper presented at the Neuroendocrinology, 2017.
41. Raj, N., Chan, J., Dasari, A., Capanu, M., Tang, L., & Reidy-Lagunes, D.. A Phase II Trial of LEE011 in Combination With Everolimus in the Treatment of AdvancedWell Differentiated Neuroendocrine Tumors of Foregut Origin. Paper presented at the Pancreas, 2017.
42. Shen, C., Dasari, A., Chu, Y., Zhou, S., Halperin, D., Yao, J., & Shih, Y.-. Functional Status and Costs of Care During the First Year After Diagnosis of Neuroendocrine Tumors Amng Elderly Patients. Paper presented at the Pancreas, 2017.
43. Chun, Y. S., Mehran, R. J., Tzeng, C.-W. D., Kee, B. K., Dasari, A., Sepesi, B., Conrad, C., Aloia, T. A., Kopetz, S., & Vauthey, J.-N. LUNA: A randomized phase II trial of liver resection plus chemotherapy or chemotherapy alone in patients with unresectable lung and resectable liver metastases from colorectal adenocarcinoma:. American Society of Clinical Oncology, 2017.
44. Dasari A, Mehta K, Byers L, Sorbye H, Yao J. Comparative Study of Pulmonary and Extrapulmonary High Grade Neuroendocrine Carcinomas: A SEER Database Analysis of 210195 Cases. NANETS 2016, 2016.
45. Dasari A, Shen C, Halperin D, Zhou S, Xu Y, Chu Y, Shih T, Yao J. Survival Trends in Neuroendocrine Tumors and Associated Prognostic Factors. NANETS 2016, 2016.
46. Raj N, Chan J, Dasari A, Capanu M, Tang L, Reidy-Lagunes D. A Phase II Trial of LEE011 in Combination with Everolimus in the Treatment of Advanced Well Differentiated Neuroendocrine Tumors of Foregut Origin. NANETS 2016, 2016.
47. Mehrvarz S, Advani S, Patel M, Dasari A. Prognostic validity of AJCC staging system in neuroendocrine tumors of the appendix. ESMO 2016, 2016.
48. Dasari A, Daniel M. Halperin, Shouhao Zhou, Yiyi Chu, Ying Xu, Tina Shih, James C. Yao, Chan Shen. Clinicopathological and demographic factors associated with development of distant metastasis among patients with locoregional neuroendocrine tumor (NET). J Clin Oncol 34, 2016.
49. Dasari A, Michael J. Overman, David R. Fogelman, Bryan K. Kee, David Menter, Kanwal Pratap Singh Raghav, Van Karlyle Morris, Jisu Oh, Ji Wu, Zhiqin Jiang, Feng Tian, Liana Adam, Mary Brimer, Jeffrey Morris, Funda Meric-Bernstam, Scott Kopetz. A phase II and co-clinical study of an AKT inhibitor in patients (pts) with biomarker-enriched, previously treated metastatic colorectal cancer (mCRC) 34, 2016.
50. Chan Shen, Dasari A, Shouhao Zhou, Yiyi Chu, Ying Xu, Ya-Chen T. Shih, James C. Yao, Daniel M. Halperin. Functional status of neuroendocrine tumors among elderly patients: A large population-based study using SEER-Medicare data. 2016 ASCO Annual Meeting 34, 2016.
51. Alexandria T. Phan, Dasari A, Nilani Liyanage, David Cox, Susan Pitman Lowenthal, Edward M. Wolin. Tumor response in the CLARINET study of lanreotide depot vs. placebo in patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs). 2016 Gastrointestinal Cancer Symposium 34, 2016.
52. Amir Mehrvarz Sarshekeh, Michael J. Overman, Bryan K. Kee, David R. Fogelman,Dasari A, Kanwal Pratap Singh Raghav, Eduardo Vilar Sanchez, Shanequa Manuel, Imad Shureiqui, Robert A. Wolff, Keyur Patel, Rajyalakshmi Luthra, Kenna Rael Shaw, Cathy Eng, Dipen M. Maru, Mark Routbort, Funda Meric-Bernstam, Scott Kopetz. Demographic, tumor characteristics, and outcomes associated with SMAD4 mutation in colorectal cancer. 2016 Gastrointestinal Cancer Symposium 34, 2016.
53. Korphaisarn K, Overman MJ, Fogelman DR, Kee BK, Raghav KPS, Shureiqui I, Wolff RA, Patel K, Shaw KR, Eng C, Maru DM, Routbort M, Meric-Bernstam F, Kopetz S, Morris VK, Vilar-Sanchez E, Manuel S,Dasari A,. Association of FBXW7 missense mutations (mt) with unfavorable prognosis in metastatic colorectal cancer (mCRC) patients (pts). 2016 ASCO Annual Meeting 34, 2016.
54. Rudek, M. A., Dasari, A., Laheru, D., He, P., Jin, R., Walker, R., Taylor, G. E., Jimeno, A., Donehower, R. C., & Hidalgo, M.. Phase 1 study of ABT‐751 in combination with CAPIRI (capecitabine and irinotecan) and bevacizumab in patients with advanced colorectal cancer. The Journal of Clinical Pharmacology 56(8):966-973, 2016.
55. Dasari, A., Shen, C., Halperin, D., Zhou, S., Xu, Y., Chu, Y., Shih, T., & Yao, J.. Survival trends of neuroendocrine tumors and associated prognostic factors, 2016.
56. Iwasaki, M., Wolin, E., Dasari, A., Liyanage, N., Lowenthal, S. P., & Phan, A. Response Rates with Lanreotide in the Phase III CLARINET Trial in Gastroenteropancreatic NETs (GEP-NETs), 2016.
57. Phan, A. T., Dasari, A., Liyanage, N., Cox, D., Lowenthal, S. P., & Wolin, E. M.. Tumor response in the CLARINET study of lanreotide depot vs. placebo in patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs):. American Society of Clinical Oncology, 2016.
58. Overman MJ, Kee BK, Fogelman DR, Eng C, Vilar Sanchez E, Shroff RT,Dasari A, Wolff RA, Morris J, Kopetz S. A phase II study of nab-paclitaxel in refractory CIMP-high metastatic colorectal cancer. J Clin Oncol 33, 2015.
59. Dasari A,. Lanreotide depot/autogel (LAN) in midgut neuroendocrine tumors (NETs): A subgroup analysis from the CLARINET study. 2015 ASCO Annual Meeting, 2015.
60. Dasari A, Phan A, Gupta S, Hess KR, Culotta KS, Rashid A, Yeung SJ, Chen HX, Dong M, Halperin DM, Subbiah IM, Meric-Bernstam F Yao JC.. A phase I study of the anti-IGF-1R monoclonal antibody (MoAb), IMC-A12 (I), and everolimus (E) in well differentiated neuroendocrine tumors (WD NET). 2014 ASCO Annual Meeting 32(3):232, 2014.
61. Conte B, George B, Dasari A, Overman MJ, Estrella J, Jiang Z, Machado K, Mello CL, Ferrarotto R, Hoff PM, Yao JC, Rashid A, Kopetz S. Colorectal high grade neuroendocrine carcinoma: a single institution experience. ASCO Annual Meeting 32(2):540, 2014.
62. Morris VK, Overman MJ, Kee BK, Fogelman DR, Eng C, Dasari A, Shroff RT, Deaton, Manuel L, Garrett CR, Sanchez V, Pini E, Shureiqi TM, Mills GB, Hamilton SR, Wolff RA, Meric-Bernstam F, Abbruzzese JL, Maru DM, Kopetz S. Efficiency of biomarkers screening for enriched metastatic colorectal cancer trials: The ATTACC program experience. GI ASCO Meeting 32(3):540, 2014.
63. Bugano Diniz Gomes D, Hassabo HM, Al Mutar SS, Sahin IH, Rogers J, Nguyen DV, Bolonesi RM, Pini TM, Dasari A, Kopetz S, Overman MJ, Eng C, Kee BK, Hassan M, Garrett CR. MD Anderson experience with off study regorafenib in patients with advanced colorectal cancer. ASCO Annual Meeting 32(3):635, 2014.
64. Morris VK, Overman MJ, Kee BK, Fogelman DR, Eng C, Dasari A, Shroff RT, Deaton K, Manuel S, Garrett CR, Vilar Sanchez E, Pini TM, Shureiqi I, Mills GB, Hamilton SR, Wolff RA, Meric-Bernstam F, Abbruzzese JL, Maru DM, Kopetz S. Efficiency of biomarker screening for enriched metastatic colorectal cancer trials: The ATTACC program experience. 2014 Gastrointestinal Cancers Symposium 32, 2014.
65. Hesham M. Hassabo, Ibrahim Halil Sahin, Syed Mohammad Ali Kazmi, Salwan S. Al Mutar, Diogo Bugano Diniz Gomes, Tunghi May Pini, Eduardo Vilar Sanchez,Dasari A,Scott Kopetz, Michael J. Overman, Cathy Eng, Bryan K Kee, Jean-Nicolas Vauthey, Manal Hassan, Chris R. Garrett. Associations between patient (pt) colorectal cancer (CRC) tumor KRAS and BRAF mutation (mut) status and overall survival (OS). 2014 Gastrointestinal cancer Symposium 32, 2014.
66. Kopetz S, Overman MJ, Chen K, Lucio-Eterovic AK, Kee BK, Fogelman DR,Dasari A, Raghav KPS, Vilar Sanchez E, Phillips J, Shureiqi I, Garrett CR, Wolff RA, Patel K, Aldape KD, Luthra R, Routbort M, Maru DM, Meric-Bernstam F, Eng C. Mutation and copy number discordance in primary versus metastatic colorectal cancer (mCRC). 2014 ASCO Annual Meeting 32:5s, 2014.
67. Subbiah, I. M., Dasari, A., Escano, M., Dagohoy, C., & Yao, J. C.. Exploratory Analysis of Early Response Signals Using Targeted Therapies for the Treatment of Advanced Carcinoid Tumor of the Kidney, 2014.
68. Dasari A, Gao H, Deaton L, Overman MJ, Hauch S, Kopetz S, Reuben JM. Association of mesenchymal phenotype in circulating tumor cells with poor prognosis in metastatic colorectal cancer. ASCO 2013 Annual Meetings, J Clin Oncol 31, 2013.
69. Morelli MP, Overman MJ, Dasari A, Kazmi SMA, Vilar Sanchez E, Eng C, Kee BK, Deaton L, Garrett CR, Diehl F, Angenendt P, Kopetz S. Heterogeneity of acquired KRAS and EGFR mutations in colorectal cancer patients treated with anti-EGFR monoclonal antibodies. ASCO 2013 Meetings, J Clin Oncol 31, 2013.
70. Morelli, M. P., Overman, M., Dasari, A., Kazmi, A., Vilar-Sanchez, E., Eng, C., Kee, B., Deaton, L., Garrett, C., & Diehl, F. Abstract B35: Acquired KRAS mutations after anti-EGFR therapy partially derive from low-frequency clones detectable in the primary tumor:. American Association for Cancer Research, 2013.
71. Lemos, R., Kopetz, S., Jiang, Z., Dasari, A., Maru, D., & Powis, G.. Patient-derived Metastatic Colorectal Cancer Mouse Tumorgrafts for Anticancer and Mechanism Studies. European Journal of Cancer 48:20-21, 2012.
72. Messersmith, W., LoRusso, P., Cleary, J., Dasari, A., Huang, B., Shaik, N., Cesari, R., McLachlan, K., Kern, K., & Shapiro, G.. 588 A First-in-patient Phase I Study of the Novel Gamma Secretase Inhibitor PF-03084014 in Patients with Advanced Solid Tumor Malignancies. European Journal of Cancer 48:180, 2012. e-Pub 2012.
73. Powell RW, Tan AC, Varella-Gacia M, Touban B,Dasari A, Puls L, Pitts L, Kulikowski G, Quackenbush K, Messersmith W, Arcaroli JJ. Biomarkers for sensitivity to gamma secretase inhibitors in mouse models of pancreatic adenocarcinoma. American Association for Cancer Research, 2011.
74. Dasari A, MA Rudek, J Arcaroli.,RW Powell, MA Carducci, D Laheru, JJ Wright, M Hidalgo, WA Messersmith. Tolerance of full-dose sorafenib (S) combined with irinotecan (i;weekly, two on one off) and cetuximab (C) in previously treated patients with advanced colorectal cancer (CRC). ASCO Annual Meeting 29(4):522, 2011.
75. Messersmith WA, LoRusso P, Cleary JM, Dasari A, Zhang X, Shaik MN, Courtney RD, Randoulph S, Shapiro G. A Phase I dose-escalation study of the novel gamma secretase inhibitor PF-03084014 in patients (pts) w ith advanced solid tumors. ASCO Annual Meeting 29(15):3100, 2011.
76. Dasari, A., Rudek, M., Arcaroli, J., Powell, R., Carducci, M., Laheru, D., Wright, J., Hidalgo, M., Messersmith, W., & Azad, N.. Tolerance of full-dose sorafenib (S) combined with irinotecan (I; weekly, two on, one off) and cetuximab (C) in previously treated patients with advanced colorectal cancer (CRC). Journal of Clinical Oncology 29(4):522-522, 2011.
77. 6. Messersmith, W., LoRusso, P., Cleary, J., Dasari, A., Zhang, X., Shaik, M., Courtney, R., Randolph, S., & Shapiro, G. A phase I dose-escalation study of the novel gamma secretase inhibitor PF-03084014 in patients (pts) with advanced solid tumors. Journal of Clinical Oncology 29(15):3100-3100, 2011.
78. Powell, R. W., Tan, A. C., Varella-Garcia, M., Touban, B., Dasari, A., Puls, L., Pitts, T., Kulikowski, G., Quackenbush, K., & Messersmith, W. Biomarkers of sensitivity to PF-03084014, a γ-secretase Inhibitor, in a preclinical model of colorectal cancer:. American Association for Cancer Research, 2011.
79. Dasari A, Gore L, Messersmith AW, Diab S, Jimeno A, Weekes CD, Lewis KD, Drabkin HA, Flaig TW, Camidge DR. A Phase I Safety and Tolerability Study of Vorinostat (V) in Combination with Sorafenib (S) in Patients With Advanced Solid tumors, With Exploration of Two Tumor-Type Specific Expanded Cohorts at the Recommended Phase II Dose (Renal and Non-Small Cell Lung Carcinoma). ASCO Annual Meeting 2010, 2010.
80. Powell RW, Messersmith W, Garcia M, Tan AC, Touban B, Pitts T, Dasari A. The combination of PF03084014 (a γ-secretase inhibitor) and Irinotecan reduces ALDH+ tumor-initiating cells and recurrence in tumors with elevated notch pathway. AACR 2010, 2010.
81. Dasari A, S Malhohrta., CL Spanoletti. A rare complication of a common disease: Pyogenic liver abscess due to diverticulitis. SGIM Meeting 2008 Annual Meeting Proceedings JGIM 23(2):89-443, 2008.
82. Malthtra S, A Lertratanakul., Dasari A, CL Spagnoletti. An unusual cause for low back pain: Mycotic abdominal aneurysm. SGIM Meeting 2008 Annual Meeting Proceedings JGIM 23(2):89-443, 2008.
83. Dasari A, S Malhotra., CL spagnoletti. Sore Throat - Not always the usual suspect. SGIM Meeting 2008 Annual Meeting Proceedings JGIM 23(2):89-443, 2008.
84. Bartholomew, J., Dasari, A., Volonte, D., & Galbiati, F.. Oxidative Stress Induces Premature Senescence by Stimulating Caveolin-1 Gene Transcription through p38 MAPK/Sp 1-mediated Activation of Two GC-rich Promoter Elements, 2006.

Book Chapters

1. Dasari A, Johnson B, Parseghian P, Raghav K, Kopetz S,. In: Colorectal Cancer In: The MD Anderson Manual of Medical Oncology. 4th. McGraw-hill, 2022.
2. Makawita S, Dasari A,. In: Liquid Biopsies in Gastrointestinal Cancers In: Handbook of Targeted Cancer Therapy and Immunotherapy: Gastrointestinal Cancer. 1st. Wolters Kluwer, 2022.
3. Rebecca A. Snyder, Arvind Dasari, Y. Nancy You. Liquid Biopsy. In: Colorectal Liver Metastasis, 2022.
4. Das, S., Soares, H., Dasari, A. In: Neoadjuvant and Adjuvant Treatment Strategies for Well-Differentiated Neuroendocrine Tumors Neuroendocrine Tumors, 75-86, 2021.
5. Dasari A, Yao JC. Pancreatic neuroendocrine tumors. In: Textbook of Complex General Surgical Oncology. McGraw-Hill, 2014.
6. Dasari A, Das P. Could upfront chemotherapy substitute preoperative radiochemotherapy?. In: Multidisciplinary Management of Rectal Cancer - Questions and Answers, 2014.
7. Dasari A, Messersmith WA. Colorectal Cancer. In: Clinical Decision Support System on Oncology, 2008.